6/10/2023

Janusmed kön och genus

Janusmed kön och genus – Flukonazol 2care4

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Flukonazol

Flukonazol

Klass: A

Visa all info

Skriv ut

Kontakta oss

Produkter

Visa alla produkter

Diflucan, Fluconazol Actavis, Fluconazol Aurobindo, Flu......

Diflucan, Fluconazol Actavis, Fluconazol Aurobindo, Fluconazol Bluefish, Fluconazol Copyfarm, Fluconazol Fresenius Kabi, Fluconazol HEXAL, Fluconazol Hexal, Fluconazol Krka, Fluconazol Navamedic, Fluconazol Paranova, Fluconazol Pharmathen, Fluconazol Takeda, Fluconazole, Fluconazole Abacus Medicine, Fluconazole Accord, Fluconazole B. Braun, Fluconazole Baxter, Fluconazole CC Pharma, Flukonazol 2care4, Flukonazol Ebb, Flukonazol Medartuum, Flukonazol Mylan, Larfungo, Solona
ATC-koder

J02AC01

J02AC01
Substanser

flukonazol

flukonazol
Sammanfattning

Det saknas publicerade kontrollerade studier om könsskillnader avseende effekt hos vuxna.

Det saknas publicerade kontrollerade studier om könsskillnader avseende effekt hos vuxna.
Background

Pharmacokinetics and dosing
A pharmacokinetic study in healthy volunteers (26 men, 33 women) receiving an oral dose of fluconazole 100 mg showed that women had 36% higher Cmax, 17% lower volume of distribution and 20% shorter half-life than men, after adjusting for total bodyweight. The authors suggest that the observed differences in volume of distribution are likely because of differences in total body water, which generally is higher in men [1]. Similar results were observed in a study in Chinese volunteers (5 men, 5 women) receiving fluconazole 200 mg single dose [2]. A study in HIV-positive patients (93 men, 29 women) observed no effect on patient’s sex on fluconazole pharmacokinetics [3].

Effects
Fluconazole efficacy was compared with nystatin in a randomized study in immunocomprised children with oropharyngeal thrush (in total 182, 5 months-14 years old). No differences in responses between girls and boys were observed (data not shown). Reported side effects were not stratified by patient's sex [4].

Adverse effects
Fluconazole has been associated with rare cases of seri......

Visa hela bakgrundstexten

# Pharmacokinetics and dosing A pharmacokinetic study in healthy volunteers (26 men, 33 women) receiving an oral dose of fluconazole 100 mg showed that women had 36% higher Cmax, 17% lower volume of distribution and 20% shorter half-life than men, after adjusting for total bodyweight. The authors suggest that the observed differences in volume of distribution are likely because of differences in total body water, which generally is higher in men [1]. Similar results were observed in a study in Chinese volunteers (5 men, 5 women) receiving fluconazole 200 mg single dose [2]. A study in HIV-positive patients (93 men, 29 women) observed no effect on patient’s sex on fluconazole pharmacokinetics [3]. # Effects Fluconazole efficacy was compared with nystatin in a randomized study in immunocomprised children with oropharyngeal thrush (in total 182, 5 months-14 years old). No differences in responses between girls and boys were observed (data not shown). Reported side effects were not stratified by patient's sex [4]. # Adverse effects Fluconazole has been associated with rare cases of serious hepatic toxicity, but no obvious relationship to sex or age of the patient has been observed. Caution is recommended if fluconazole is used in patients with liver dysfunction [5]. # Reproductive health issues Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Fler kvinnor än män hämtade ut läkemedel innehållande flukonazol (ATC-kod J02AC01) på recept i Sverige år 2015, totalt 76 600 kvinnor och 11 760 män. Det motsvarar 16 respektive 2 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 25-29 år hos kvinnor och i åldersgruppen 85 år och äldre hos män. I genomsnitt var läkemedel innehållande flukonazol 8,1 gånger vanligare hos kvinnor [6].
Referenser

Visa referenser

  1. Carrasco-Portugal Mdel C, Flores-Murrieta FJ. Gender differences in the oral pharmacokinetics of fluconazole. Clin Drug Investig. 2007;27:851-5.

  2. Guo T, Sun WJ, Xia DY, Zhao LS. The pharmacokinetics of fluconazole in healthy Chinese adult volunteers: influence of ethnicity and gender. J Clin Pharm Ther. 2010;35:231-7.

  3. Csajka C, Décosterd LA, Buclin T, Pagani JL, Fattinger K, Bille J et al. Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. Eur J Clin Pharmacol. 2001;57:723-7.

  4. Flynn PM, Cunningham CK, Kerkering T, San Jorge AR, Peters VB, Pitel PA et al. Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin The Multicenter Fluconazole Study Group. J Pediatr. 1995;127:322-8.

  5. Diflucan (flukonazol). Summary of Product Characteristics. Medical Products Agency Sweden; 2015.

  6. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-08-02.]

  1. Carrasco-Portugal Mdel C, Flores-Murrieta FJ. Gender differences in the oral pharmacokinetics of fluconazole. Clin Drug Investig. 2007;27:851-5.
  2. Guo T, Sun WJ, Xia DY, Zhao LS. The pharmacokinetics of fluconazole in healthy Chinese adult volunteers: influence of ethnicity and gender. J Clin Pharm Ther. 2010;35:231-7.
  3. Csajka C, Décosterd LA, Buclin T, Pagani JL, Fattinger K, Bille J et al. Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. Eur J Clin Pharmacol. 2001;57:723-7.
  4. Flynn PM, Cunningham CK, Kerkering T, San Jorge AR, Peters VB, Pitel PA et al. Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin The Multicenter Fluconazole Study Group. J Pediatr. 1995;127:322-8.
  5. Diflucan (flukonazol). Summary of Product Characteristics. Medical Products Agency Sweden; 2015.
  6. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-08-02.]
Uppdaterat

Litteratursökningsdatum 8/2/2016

Litteratursökningsdatum 8/2/2016